The field of testing, analytics and in vitro models is entering a pivotal era, driven by technological breakthroughs and shifting regulatory and ethical priorities. The global in vitro toxicology testing market, for instance, was valued at $31.03 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 11.1%, reaching $64.81 billion by 2030.1 This growth underscores the increasing reliance on innovative, human-relevant testing methods that reduce the need for animal models while delivering robust, reproducible data.
In the realm of skin research, the in vitro skin model market is also experiencing significant expansion, with a forecasted value of $4.5 billion by 2029, growing at a CAGR of 7%.2 This growth is fueled by advancements in 3D cell culture technologies, which enable the development of physiologically relevant models for drug efficacy, safety assessments, and toxicity testing. Reconstructed human epidermis (RHE) models, for example, dominate the market due to their widespread application in irritation testing and skin permeability studies.
Research continues to push the boundaries of in vitro methodologies. For example, the development of 3D bioprinted skin models and microfluidic devices has enhanced the precision and applicability of these systems.2 Additionally, initiatives like the Collaborative Programs Tox21, which employs high-throughput screening (HTS) for chemical safety testing, exemplify the integration of cutting-edge technology into toxicology research.1
These advancements not only address regulatory and ethical challenges, but also pave the way for more predictive and efficient R&D processes. By combining in vitro models with AI-driven analytics and in silico approaches, researchers can rapidly screen formulations, optimize ingredient combinations, and predict clinical outcomes with greater accuracy.
This convergence of technologies is setting a new benchmark for innovation in cosmetics and personal care research. To explore these transformative trends further, we turned to industry experts for their firsthand insights into the latest advancements, challenges and opportunities shaping the field.
Advances in Data Analytics and In vitro Models
Diana Khazaka, general manager at Courage + Khazaka, believes that while classical efficacy studies and safety assessments in human volunteers remain essential, there is a strong shift toward advanced in vitro testing strategies. “Beyond pharmaceutical research, in vitro models are increasingly adopted in cosmetic R&D to address regulatory, ethical and scientific demands,” she writes. “Human-relevant barrier models, such as reconstructed skin or epithelial cultures, are widely used to assess permeability, irritation and barrier integrity.”
She adds that modern in vitro transepidermal water loss (TEWL) test methods and electrical barrier assessment technologies, such as transepithelial electrical resistance (TEER), enable real-time, non-invasive monitoring of tissue integrity in up to 24 cell culture inserts simultaneously. “These approaches deliver quantitative, reproducible data while simplifying workflows and data analysis,” she explains, adding that combined with in vivo data, in vitro testing has become an efficient tool for evaluating cosmetic ingredients and formulations. “The increasing focus on longevity further highlights the importance of mechanistic research, where in vitro models play a key role,” Khazaka emphasizes.
These trends are expected to converge toward predictive platforms. Per Khazaka, combined with AI-driven models and in silico approaches based on large datasets, advanced in vitro methods will increasingly serve as screening and decision-making tools in R&D. “They enable rapid formulation comparison and early selection of optimal candidates before costly clinical trials, while complementing classical in vivo testing, which remains essential.”
Moving forward, Khazaka anticipates advanced data analytics, machine learning and digital tools support the interpretation of complex datasets from modern in vitro platforms. “When combined with benchmark skin measurement instruments and structured data management, these technologies enable robust retrospective and cross-study analyses,” she concludes.
Multi-Test Combos and Market Differentiation
"Current testing trends reflect both regulatory challenges and evolving consumer expectations,” observes Eurofins. “There is a strong focus on the safety of specific ingredients and finished products – such as for PFAS, nanomaterials and microplastics.”
According to Eurofins, efficacy testing is increasingly supported by advanced image analysis and protocols, which enables objective, quantitative measurements to substantiate strong performance claims such as up to 3× smoother skin. “In parallel, makeup testing continues to evolve, driven by skinification, with tailored methodologies designed to assess not only performance, wear and visual impact, but also skin-related benefits,” the company adds, also highlighting: “additionally, pet care products are gaining attention.”
In terms of future directions in testing, Eurofins expects safety assessments will continue gaining importance, alongside growing demand for more meaningful and differentiated efficacy claims. “Future testing strategies will increasingly combine multiple test types, conducted in parallel, leveraging the complementarity of different approaches – such as clinical and emotional assessments, or ex vivo, clinical and consumer studies – to generate richer and more actionable data,” the company explains.
“The development of new claims, such as age gain concepts, will drive demand for innovative study designs,” the company continues. In relation, new equipment and methodologies will enable more comprehensive evaluations, supporting both regulatory compliance and marketing differentiation.
To support these market directions, Eurofins points to emerging technologies such as LC-OCT (Line-field Confocal Optical Coherence Tomography) that will play a key role by enabling non-invasive, high-resolution skin analysis. “Artificial intelligence will further enhance image analysis and data interpretation, improving precision and efficiency. In addition, new in vitro and ex vivo models will support both safety and efficacy testing.”
Physiological Relevancy and Broader AI Adoption
Jocelyn Kearsley, senior technical sales manager for Genemarkers, LLC, underscores that validating safety and efficacy is a must-have as the industry shifts its focus from aesthetics to scientific validation. “Industry leaders are turning to ex vivo human skin and hair follicle models, reconstructed epidermis systems, and omics-based approaches to generate data,” she explains. “Human-relevant models can provide scientific support for claims including barrier repair, inflammation, pigmentation, microbiome support, senescence and oxidative stress.”
Kearsley also sees testing happening earlier in the development process. “Studies using in vitro cells and tissue models can help select actives, refine concentrations and optimize combinations before initiating more expensive clinical studies.”
Looking ahead, she projects future strategies will integrate multi-modal datasets combining histology, transcriptomics, proteomics and computational modeling. “We predict increased use of high-throughput technologies to facilitate pathway-based approaches, such as demonstrating how a product modulates inflammation cascades or influences collagen synthesis networks,” she explains.
What’s more, Kearsley expects the broader adoption of AI-assisted biomarker interpretation to identify responder profiles, optimize ingredient combinations and predict clinical outcomes. “This can support more targeted product positioning for subpopulations, including sensitive and menopausal skin or post-procedure care.”
The increased use of tools and technologies that test formulations and actives under physiologically relevant conditions will support these market dynamics. “Techniques such as histology and immunohistochemistry will be coupled with biomarker platforms like Meso Scale Discovery (MSD), for more comprehensive screening,” Kearsley writes.
“Histology provides spatial resolution of factors, such as epidermal thickness, collagen deposition and inflammatory markers, while biomarker analysis quantifies cytokines, MMPs, growth factors and oxidative stress markers. Together, these technologies allow brands to screen formulations, optimize concentrations and build mechanism-based claims.”
‘Evidence Packages,’ Biology Linked and Longitudinal
“Safety testing is shifting toward animal-free, human-relevant evidence,” observes Lun Yu, chief technology officer for Metanovas Biotech. “The dominant approach is to combine exposure estimates with non-animal laboratory assays and computational models, documented as an integrated safety case.”
According to Yu, efficacy testing is becoming more quantitative: instrument-based measures (barrier function, hydration, elasticity, imaging-based wrinkle/texture metrics) are increasingly preferred over purely subjective claims. “Noninvasive techniques that strengthen mechanisms and delivery narratives, such as confocal Raman spectroscopy, are also gaining traction,” he explains.
Yu believes these trends will converge into standardized, reproducible “evidence packages” that support more endpoints beyond sensitization and irritation – with stronger documentation, quality systems and decision rules that are defensible across regions. “The biggest near-term potential is improving translation and speed by moving more testing into microphysiological human tissue platforms,” he says.
“This includes skin-on-a-chip and advanced three-dimensional skin systems that enable longer time-course biology (inflammation, pigmentation, barrier recovery, repair) and earlier go/no-go decisions,” Yu continues. In parallel, he sees efficacy substantiation becoming “more biology-linked and longitudinal,” with higher-frequency measurements in smaller cohorts, better baseline stratification (e.g., barrier-impaired versus oil-prone) and tighter linkage between instrumental endpoints and molecular readouts.
“Skin-on-a-chip platforms enable these directions by capturing longer-lived, tissue-level responses under controlled exposure, especially barrier recovery kinetics, inflammation resolution and repair-like remodeling, providing more human-relevant readouts than simple cell assays,” Yun writes, adding that in silico models enable scale and consistency. They achieve this by triaging large ingredient and formulation spaces, quantifying real-world exposure and margins of safety, and supporting defensible read-across and decision-making when experimental coverage is incomplete, per Yun.
Conclusion
The integration of advanced in vitro models, AI-driven analytics and innovative methodologies is revolutionizing R&D, offering ethical and efficient alternatives to traditional testing. As these technologies evolve, they promise to redefine industry standards, paving the way for more human-relevant and impactful research.
References
- Grand View Research. (Accessed 2026, Feb 11). In vitro toxicology testing market (2024 - 2030). Available at https://www.grandviewresearch.com/industry-analysis/in-vitro-toxicology-testing-market
- Market Report Analytics. (2026, Jan 27). In vitro skin model strategic insights for 2025 and forecasts to 2033: Market trends. Available at https://www.marketreportanalytics.com/reports/in-vitro-skin-model-26937
